During the last session, Enliven Therapeutics Inc (NASDAQ:ELVN)’s traded shares were 0.51 million, with the beta value of the company hitting 0.83. At the end of the trading day, the stock’s price was $18.42, reflecting an intraday loss of -1.13% or -$0.21. The 52-week high for the ELVN share is $30.03, that puts it down -63.03 from that peak though still a striking 27.8% gain since the share price plummeted to a 52-week low of $13.30. The company’s market capitalization is $903.80M, and the average trade volume was 272.21K shares over the past three months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
Enliven Therapeutics Inc (ELVN) registered a -1.13% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.13% in intraday trading to $18.42, hitting a weekly high. The stock’s 5-day price performance is -10.19%, and it has moved by 11.50% in 30 days. Based on these gigs, the overall price performance for the year is -25.43%.
The consensus price target of analysts on Wall Street is $39.5, which implies an increase of 53.37% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $39 and $40 respectively. As a result, ELVN is trading at a discount of -117.16% off the target high and -111.73% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.02%. While earnings are projected to return -16.22% in 2025, the next five years will return -18.00% per annum.
ELVN Dividends
Enliven Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 5.69 million shares, is of FMR LLC’s that is approximately 11.8452% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $133.08 million.
Also, the Mutual Funds coming in first place with the largest holdings of Enliven Therapeutics Inc (ELVN) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.12 shares. This amounts to just over 2.28 percent of the company’s overall shares, with a $20.64 million market value. The same data shows that the other fund manager holds slightly less at 957.74, or about 1.95% of the stock, which is worth about $17.64 million.
